Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
*2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. ''(Based on QuANTUM-First)'' | *2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. ''(Based on QuANTUM-First)'' | ||
*2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. ''(Based on QuANTUM-First)'' | *2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. ''(Based on QuANTUM-First)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *2023-09-14: CHMP recommended marketing authorization at Vanflyta. Vanflyta would be indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive. | ||
| + | |||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive [[acute myeloid leukemia]]. | *2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive [[acute myeloid leukemia]]. | ||
Revision as of 12:32, 1 October 2023
Mechanism of action
FLT3 inhibitor
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-07-20: Approved with standard cytarabine and anthracycline induction for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
History of changes in EMA indication
- 2023-09-14: CHMP recommended marketing authorization at Vanflyta. Vanflyta would be indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
History of changes in PMDA indication
- 2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.
Also known as
- Code names: AC-220, ASP-2689
- Brand name: Vanflyta